Malaria

Defining and validating a measure of parasite resistance to sulfadoxine-pyrimethamine (SP) that would be indicative of the protective efficacy of SP for intermittent preventive treatment in infancy (IPTi-SP)

Report of the technical consultation, Geneva, 10-11 September 2009

Share

Authors:
World Health Organization


Overview

Intermittent preventive treatment in infancy (IPTi) is the administration of a full course of an effective antimalarial treatment to infants at risk of malaria at specified time points, regardless of whether or not they are parasitaemic, with the objective of reducing the infant malaria burden.

The protective efficacy of IPTi with sulfadoxine-pyrimethamine (IPTi-SP) is dependent upon the antimalarial efficacy of SP, to which there has been increasing parasite resistance in most parts of Africa. This is the report of a technical expert consultation convened by GMP in September 2009 to identify the most appropriate marker(s) of SP resistance and their threshold levels that would be indicative of the protective efficacy of SP in IPTi, to guide the deployment of IPTi-SP in a given area.

Related document